breast cancer



Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

  • The company on Friday said the relative risk reduction of cancer recurrence was 25.2%
  • The results were broadly consistent regardless of patients' menopausal status or cancer progression status
By Reuters ·